UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000060542 |
|---|---|
| Receipt number | R000066680 |
| Scientific Title | Research trends on the use of blonanserin for delirium: a scoping review |
| Date of disclosure of the study information | 2026/02/01 |
| Last modified on | 2026/02/01 01:37:05 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Research trends on the use of blonanserin for delirium: a scoping review
Acronym
Research trends on the use of blonanserin for delirium: a scoping review
Scientific Title
Research trends on the use of blonanserin for delirium: a scoping review
Scientific Title:Acronym
Research trends on the use of blonanserin for delirium: a scoping review
Region
| Japan |
Condition
Condition
delirium
Classification by specialty
| Psychiatry |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To systematically map existing literature on the use of blonanserin for delirium
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Research trends on the use of blonanserin for delirium
Key secondary outcomes
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Research on the use of blonanserin for delirium in medically ill.
Key exclusion criteria
1) Duplicate publications
2) Research for subjects with other psychiatric diagnosis (e.g., Schizophrenia, Bipolar disorder)
3) Articles written in languages other than English or Japanese
Target sample size
Research contact person
Name of lead principal investigator
| 1st name | MAKOTO |
| Middle name | |
| Last name | KOBAYAKAWA |
Organization
Hiroshima Red cross Hospital and Atomic-bomb survivors Hospital
Division name
Department of psychiatry
Zip code
7308619
Address
1-9-6 senda-machi naka-ku Hiroshima
TEL
082-241-3111
newgundamyamato@gmail.com
Public contact
Name of contact person
| 1st name | MAKOTO |
| Middle name | |
| Last name | KOBAYAKAWA |
Organization
Hiroshima Red cross Hospital and Atomic-bomb survivors Hospital
Division name
Department of Psychiatry
Zip code
7308619
Address
1-9-6 senda-machi naka-ku Hiroshima
TEL
082-241-3111
Homepage URL
newgundamyamato@gmail.com
Sponsor or person
Institute
Hiroshima Red cross Hospital and Atomic-bomb survivors Hospital
Institute
Department
Personal name
MAKOTO KOBAYAKAWA
Funding Source
Organization
self funding
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
NP
Address
NP
Tel
082-241-3111
newgundamyamato@gmail.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 02 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
0
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2025 | Year | 06 | Month | 29 | Day |
Date of IRB
| 2025 | Year | 06 | Month | 29 | Day |
Anticipated trial start date
| 2025 | Year | 06 | Month | 30 | Day |
Last follow-up date
| 2025 | Year | 07 | Month | 31 | Day |
Date of closure to data entry
| 2025 | Year | 12 | Month | 31 | Day |
Date trial data considered complete
| 2026 | Year | 01 | Month | 01 | Day |
Date analysis concluded
| 2026 | Year | 01 | Month | 31 | Day |
Other
Other related information
This study examines the reports on usage of blonanserin for delirium using scoping review.
English and Japanese reports were searched through four database, PubMed, CINAHL, Cochrane Library, and Ichushi-Web on the June 30th, 2025. Studies of adult patients (over 18 years old) with delirium were included, those of patients with schizophrenia, bipolar disorders, behavioral and psychological symptoms of dementia, and other symptoms of neurological disorders were excluded.
Management information
Registered date
| 2026 | Year | 02 | Month | 01 | Day |
Last modified on
| 2026 | Year | 02 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066680
